РЕКОМЕНДАЦИИ ПО ПРОФИЛАКТИКЕ И ЛЕЧЕНИЮ ЭЗОФАГО-ГАСТРО-ЭНТЕРО-КОЛОПАТИЙ, ИНДУЦИРОВАННЫХ НЕСТЕРОИДНЫМИ ПРОТИВОВОСПАЛИТЕЛЬНЫМИ ПРЕПАРАТАМИ

нестероидные противовоспалительные препараты, антитромботические препараты, безрецептурные препараты, гастроэнтеропатия, гастроэнтеропротекторные средства, ингибиторы протонной помпы, простагландин Е2, Н2-блокаторы гистаминовых рецепторов

1. Conaghan P.G. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International. 2012;32(6):1491-1502. doi:10.1007/s00296-011-2263-6.

2. Peura D.A. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med. 2002;69Suppl 1: SI31-9.

3. Koffeman A.R, Valkhoff V.E, Çelik S. et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. The British Journal of General Practice. 2014;64(621).

4. Khan S, Mohammad A, O’Rourke K.P. An audit of the frequency of proton pump inhibitor (PPI) prescription in rheumatoid arthritis (RA) patients taking non-steroidal anti-inflammatory drugs (NSAIDs). Ir J MedSci. 2014 Dec;183(4):685-6.

5. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: Importance of cyclooxygenase inhibition and gastric hypermotility. World Journal of Gastroenterology: WJG. 2012; 18 (18): 2147-2160.

6. Unified Clinical Protocol for Primary and Secondary Medical Care Peptic Ulcer of Stomach and Duodenum in Adults, Ukraine [September, 2014]

7. Russian gastroenterological association clinical guidelines on diagnosis and treatment of NSAIDs-associated erosive and ulcerative lesions of the stomach and duodenum [Moscow, 2014]

8. Abraham N.S, Hlatky M.A, Antman E.M, Bhatt D.L, Bjorkman D.J, Clark C.B, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Am J Gastroenterol. 2010 Dec;105(12):2533-49.

9. Lanza F.L, Chan F.K, Quigley E.M; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728-738

10. NICE Guidelines: Acute upper gastrointestinal bleeding in over 16s: management. Доступ по ссылке https://www.nice.org.uk/guidance/cg141 Последний доступ: 15 сентября 2016 г.

11. Unified Clinical Protocol for Primary Medical Care Dyspepsia, Ukraine [August,2012]

12. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks [2008]. AlimentPharmacolTher. 2009 Mar 1;29(5):481-96.

13. Allison M.C, Howatson A.G, Torrance C.J, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992; 327:749-54.

14. Angel Lanas, Maarten Boers, Javier Nuevo. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. AnnRheumDis 2015; 74:675-681.

15. García Rodríguez L.A, Barreales Tolosa L (2007) Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132:498-506.

16. Moskowitz R.W, Abramson S.B, Berenbaum F, Simon L.S, Hochberg M (2007) Coxibs and NSAIDs-is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. OsteoarthrCartil 15:849-856.

17. Makris, U., Kohler, M., &Fraenkel, L. (2010). Adverse Effects (AEs) of Topical NSAIDs in Older Adults with Osteoarthritis (OA): a Systematic Review of the Literature. TheJournalofRheumatology, 37(6), 1236-1243.

18. Castellsague, J., Riera-Guardia, N., Calingaert, B., Varas-Lorenzo, C., Fourrier-Reglat, A., Nicotra, F., … Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. (2012). Individual NSAIDs and Upper Gastrointestinal Complications: A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Safety, 35(12), 1127-1146.

19. Garg A, Shoeb A, Moodahadu L.S, Sharma A, Gandhi A, and Akku S. Amtolmetin: A Reappraisal of NSAID with Gastroprotection. Arthritis. 2016; 2016: 7103705.

20. Munro H.M, Walton S.R, Malviya S, Merkel S, Voepel-Lewis T, Loder RT, Farley F.A. Low-dose ketorolac improves analgesia and reduces morphine requirements following posterior spinal fusion in adolescents. Can J Anaesth. 2002 May;49(5):461-6.

21. Fries JF, Williams CA, Bloch DA et al. Nonsteroidal anti-inflammatory drug- associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213-22.

22. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. AnnInternMed 1991; 115:787-96.

23. Koch M, Dezi A, Tarquini M, Capurso L. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. DigLiverDis. 2000 Mar;32(2):138-51.

24. Cardile S, Martinelli M, Barabino A, Gandullia P, Oliva S, Nardo G et al. Italian survey on non-steroidal anti-inflammatory drugs and gastrointestinal bleeding in children. World J Gastroenterol. 2016 Feb 7; 22(5): 1877-1883.

25. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000 Nov 11;321(7270):1183-7

26. Iijima K, Koike T, Ara N, Nakagawa K, Kondo Y, Uno K, Hatta W, Asano N, Imatani A, Shimosegawa T. Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects. J Gastroenterol. 2015 Mar;50(3):305-12

27. Yeomans N.D, Lanas A.I, Talley N.J, Thomson A.B, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment PharmacolTher. 2005; 22:795-801.

28. Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 2014; 4: e004587.

29. Chang H.Y, Zhou M, Tang W, Alexander G.C, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015 Apr 24;350: h1585.

30. Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy. 2006 Sep;26(9):1307-13.

31. Vonkeman HE, deLeest H, van deLaar M, et al. Assessment of Helicobacter pylori eradication in patients on NSAID treatment. BMC Gastroenterology. 2012; 12:133.

32. Kono Y, Okada H, Takenaka R, et al. Does Helicobacter pylori Exacerbate Gastric Mucosal Injury in Users of Nonsteroidal Anti-Inflammatory Drugs? A Multicenter, Retrospective, Case-Control Study. Gut and Liver. 2016;10(1):69-75.

33. Sokic-Milutinovic A, Krstic M, Rozer-Smolovic B, Alempijevic T. Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study. DigDisSci. 2010 Oct;55(10):2887-92.

34. Den Hollander W.J, Kuipers E.J. Current pharmacotherapy options for gastritis. Expert Opin Pharmacother. 2012 Dec;13(18): 2625-3.

35. Warlé-van Herwaarden MF, Koffeman AR, Valkhoff VE, ‘t Jong GW, Kramers C, Sturkenboom MC, De Smet PA. Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study. Br J ClinPharmacol. 2015 Sep;80(3):589-98.

36. Sebaldt RJ, Petrie A, Goldsmith CH, Marentette MA. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study. Am J ManagCare. 2004 Nov;10(11 Pt 1):742-50.

37. Ray WA, Stein CM, Byrd V, Shorr R, Pichert JW, Gideon P et al; Educational program for physicians to reduce use of non-steroidal anti-inflammatory drugs among community-dwelling elderly persons: a randomized controlled trial. MedCare. 2001 May;39(5):425-35.

38. Sung-Hun Lee, Chang-Dong Han, Ick-Hwan Yang, and Chul-Won Ha. Prescription Pattern of NSAIDs and the Prevalence of NSAID-induced Gastrointestinal Risk Factors of Orthopaedic Patients in Clinical Practice in Korea. J KoreanMedSci. 2011 Apr; 26(4): 561-567.

39. Барановский А. Ю. Диагностика, профилактика и лечение НПВП-индуцированной колонопатии. Эксп. и клин.гастроэнтерология. 2017:146(10); стр.4-14

40. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. GastroenterolClinNorthAm. 2010 Sep;39(3):433-64

41. LanasA, BenitoP, AlonsoJ, Hernández-CruzB, Barón-EsquiviasG, Perez-Aísa Á et al. Spanish Society of Rhematology; Spanish Association of Gastroenterology; Spanish Society of Cardiology. Safe prescription recommendations for non-steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG). ReumatolClin. 2014 Mar-Apr;10(2):68-84

42. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. BestPractResClinGastroenterol. 2010 Apr;24(2):121-32.

43. Natalie Schellack. An overview of gastropathy induced by nonsteroidal anti-inflammatory drugs. S AfrPharm J. 2012 Vol. 79 No 4.

44. Sugano K, Choi MG, Lin JT, Goto S, Okada Y, Kinoshita Y, Miwa H, Chiang CE, Chiba T, Hori M, Fukushima Y, Kim HS, Chang CY, Date M; LAVENDER Study Group. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2014 Jul;63(7):1061-8.

45. Scheiman JM, Lanas A, Veldhuyzen van Zanten S, Baldycheva I, Svedberg LE, Nagy P. Effect of esomeprazole on gastroduodenal erosions in patients at increased gastrointestinal risk treated with low-dose acetylsalicylic acid: a post-hoc analysis of the OBERON trial. Int J Cardiol. 2015 Mar 1; 182:500-2.

46. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296.

47. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004 Oct 23;329(7472):948.

48. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996, 334: 1435-1439.

49. Vaduganathan M, Bhatt D L, Cryer B L, Liu Y, Hsieh W H, Doros G, Cohen M, Lanas A, Schnitzer T J, Shook T L, Lapuerta P, Goldsmith M A, Laine L, Cannon C P; Исследователи COGENT. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016 Apr 12;67(14):1661-71.

50. GI Leontiadis, A Sreedharan, S Dorward, P Barton, B Delaney, CW Howden, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. NIHR Health Technology Assessment programme: Executive Summaries.

51. Mo C, Sun G, Lu M-L, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World Journal of Gastroenterology: WJG. 2015; 21(17): 5382-5392.

52. Scheiman JM, Behier EM, Loeffler KM, et al. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994; 39:97-103.

53. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998 Mar 12;338(11):727-34.

54. Graham DY, Agrawal NM, Campbell DR et al. Ulcer prevention in long-term users of nonsteroidal anti-in ammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. ArchIntern Med 2002; 162: 160-75.

55. Park S.H, Cho C.S, Lee O.Y, Jun J.B, Lin S.R, Zhou L.Y, et al. Comparison of Prevention of NSAID-Induces Gastrointestinal Complications by Rebamipide and Misoprostol: A randomised, multicenter, сontrolled trial - STORM STUDY. J ClinBiochemNutr. 2007 Mar;40(2):148-55. doi: 10.3164/jcbn.40.148.

56. Л. Б. Лазебник, В. Н. Дроздов, В. А. Ким. Эффективность фамотидина в профилактике НПВП-гастропатий. Результаты Российского многоцентрового исследования ЗАСЛОН-1 (ЗАщитаСЛизистой Оболочки желудка от Нестероидных противовоспалительных препаратов), Эксп. и клин.гастроэнт., 2009, 2, 3-9

57. Vakil N, Fennerty M.B. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. AlimentPharmacolTher. 2003 Sep 15;18(6):559-68

58. S. Agewall, M. Cattaneo J. P.Collet et al. Expert position paper on the use of proton pomp inhibitors in patients with cardiovascular disease and antitrombotic therapy. European Heart J., 2013, (34); 1708-1715.

59. Qiang Niu, Zhongsu Wang, Yong Zhang, и др. Мета-анализ: комбинированное применение клопидогреля и ингибиторов протонной помпы сопровождается увеличением частоты тяжелых нежелательных сердечно-сосудистых явлений при ишемической болезни сердца, Journal of Cardiovascular Pharmacology and Therapeutics, 1-11, © TheAuthor(s) 2016, Разрешение на перепечатку: sagepub.com/journals Permissions.nav DOI: 10.1177/1074248416663647 cpt.sagepub.com

60. Howden C.W. Review article: immediate-release proton-pump inhibitor therapy - potential advantages Aliment PharmacolTher. 2005 Dec;22Suppl 3:25-30.

61. Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert OpinPharmacother. 2005 Nov;6(14):2501-10.

62. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. AlimentPharmacolTher. 2005 Jun 15;21(12):1467-74.

63. Yeomans N, Wilson I, Långström G, Hawkey C, Naesdal J, Walan A, Wiklund I. Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol. 2001;30(6):328-34.

64. Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine vs. Omeprazole for NSAIDassociated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719-26.

65. Cullen D, Bardhan K.D, Eisner M, Kogut D.G, Peacock R.A, Thomson J.M, Hawkey C.J. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. AlimentPharmacolTher. 1998 Feb;12(2):135-40.

66. Лазебник Л.Б., Ткаченко Е. И., Абдулганиева Д. И. и др. «VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacterpylori заболеваний (VI Московские соглашения)»; Экспер. и клин.гастроэнтерология, 2017;138(2):3-19

67. vanSoest E.M, Valkhoff V.E, Mazzaglia G, Schade R, Molokhia M, Goldstein J.L, Hernández-DíazS, Trifirò G, Dieleman J.P, Kuipers E.J, Sturkenboom M.C. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011 Dec;60(12):1650-9.

68. Gigante A, Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. Clin Drug Investig. 2012 Apr 1;32(4):221-33.

69. Weinblatt, Michael E., Genovese, Mark C., Kivitz, Alan J., Bello, Alfonso E., Grahn, Efficacy, Safety And Tolerability Of HZT-501, Including Users Of Low-Dose Aspirin, A Single-Tablet Combination Of Ibuprofen-Famotidine: Results Of Two Phase 3 Trials. Arthritis&Rheumatism, Volume 62, November 2010 AbstractSupplement.

70. Sostek M.B, Fort J.G, Estborn L, Vikman K. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. CurrMedResOpin. 2011 Apr;27(4):847-54

71. Fujimori S, Hanada R, Hayashida M, Sakurai T, Ikushima I, Sakamoto C. Celecoxib Monotherapy Maintained Small Intestinal Mucosa Better Compared With Loxoprofen Plus Lansoprazole Treatment: A Double-blind, Randomized, Controlled Trial. J Clin Gastroenterol. 2016 Mar;50(3):218-26.

72. Gwen M.C Masclee, Vera E Valkhoff 1, Eva Mvan Soest, René Schade, Giampiero Mazzaglia, Mariam Molokhia, Gianluca Trifirò et al. Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? Aliment Pharmacol Ther. 2013 July; 38(2): 178-189.

73. B. P. M. Verhaegh, F. de Vries, A. A. M. Masclee, A. Keshavarzian, A. de Boer, P. C. Souverein, M. J. Pierik et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment PharmacolTher 2016; 43: 1004-1013.

74. Каратеев А.А., Насонов Е. Л., Ивашкин В. Т. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике»; Ассоциация ревматологов России, Российское общество по изучению боли, Российская Гастроэнтерологическая Ассоциация, Российское кардиологическое общество, Ассоциация травматологов-ортопедов России, Ассоциация междисциплинарной медицины, Российская ассоциация паллиативной медицины. М. 2015

75. Wiviott S D, Braunwald E, McCabe C H, Montalescot G, Ruzyllo W, et al, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.

76. Becker R.C, Bassand J.P, Budaj A, Wojdyla D.M, James S.K, Cornel J.H, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey K.W, Storey R.F, Harrington R.A, Wallentin L. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-2944.

77. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS European Heart Journal (2016) 37, 2893-2962.

78. Abraham N S, Noseworthy P A, Yao X, Sangaralingham L R, Shah N D. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology. 2017 Apr;152(5):1014-1022.

79. Miller C S, Dorreen A, Martel M, Huynh T, Barkun A N. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1674-1683.

80. Valgimigli M, Bueno H, Byrne R A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS European Heart Journal (2018) 39, 213-254.

81. Bhatt D L, Cryer B L, Contant C F, Cohen M, Lanas A, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917.

82. Hunt R, Lazebnik L.B, Marakhouski Yu.C, Manuc M, Ramesh G.N, et al. International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Induced Gastropathy - ICON-G. Euroasian Journal of Hepato-Gastroenterology. 2018; (JPJ356130218JHG) In-print.

83. Parambir S Dulai, Siddharth Singh, Evelyn Marquez, Rohan Khera, Larry J Prokop, Paul J Limburg, Samir Gupta, Mohammad Hassan Murad. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ, 2016; i6188 DOI: 10.1136/bmj.i6188

84. Final Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication. U. S. Preventive Services Task Force. September 2017. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer

85. Л. И. Бурячковская, Н. В. Ломакин, А. Б. Сумароков, Е. А. Широков. Алгоритмы и шкалы риска тромбоза и кровотечения в кардиологии и неврологии. Практическое пособие. Рекомендации Национального научного общества воспаления, Российского научного медицинского общества терапевтов, Российского научного общества специалистов по рентгенэндоваскулярной диагностике и лечению. Справочное пособие для врачей общей практики, кардиологов, неврологов. М., 2018

86. H. Decousus, V. F. Tapson, J. F. Bergmann et al. IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators //Chest. - 2011. - Vol.139, N1. - P. 69-79

87. Y. Falck-Ytter, C. W. Francis, N. A. Johanson et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest. - 2012. - Vol.141, Suppl.2. - Р.e278S-e325S

88. M. Gould, D. A. Garcia, S. M. Wren et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest. - 2012. - Vol.141, Suppl.2. - P.e227S-e277S

89. Пающик С. А. Профилактика внутрибольничных венозных тромбоэмболических осложнений с использованием информационных технологий. Дисс. к. м.н., М, 146 с